Meeting Banner
Abstract #1438

Does chemical shift imaging offer a biomarker for the diagnosis and assessment of disease severity in multiple myeloma?

Miyuki Takasu1, Takayuki Tamura1, Yuji Akiyama1, Chihiro Tani1, Yoko Kaichi1, Shota Kondo1, and Kazuo Awai1

1Department of Diagnostic Radiology, Hiroshima University Hospital, Hiroshima, Japan

We investigated whether chemical shift imaging (CSI) is useful for differentiating multiple myeloma infiltration from hematopoietic bone marrow and for quantitatively assessing disease severity. For those myeloma patients with relatively high cellularity in the bone marrow, a lower signal drop on oppose phase images indicated a higher tumor burden. For bone marrow with relatively low cellularity, disease severity was not reflected on CSI. CSI did not prove useful for differentiating myeloma infiltration from hematopoietic bone marrow, which implies that differentiation between regrowth of hematopoietic bone marrow and minimal residual disease or relapse after chemotherapy might be difficult with CSI.

This abstract and the presentation materials are available to members only; a login is required.

Join Here